Combinostics at ECTRIMS 2022

October 26-28, 2022 | Amsterdam, The Netherlands Booth C28

Did we miss you at ECRIMS 2022? Schedule a meeting with our team to learn more about our cNeuro® suite, including the cMRI™ and cDSI™ applications, and new clinically focused cMRI report for multiple sclerosis, as well as reports for dementia, traumatic brain injuries, and epilepsy. Our complete AI software solution supports entire patient care pathways of multiple sclerosis and other major neurological disorders, including early detection, differentiation of diagnosis, treatment planning, and monitoring.

Using a combination of science and innovative AI technology, we aim to make a difference in the lives of patients with neurological disorders.

Our cNeuro® suite puts the focus on patients by providing clinicians with objective, systematic insights for confident, evidence-based diagnostic and management decisions.

Patient data from multiple sources are integrated and compared with data from previous patients and healthy controls: demographic information, imaging (cMRI) and other biomarkers, clinical characteristics, and neuropsychology tests. 

Applications in the cNeuro® suite:

*WIP – not yet cleared for clinical use.
Play Video
Play Video

cDSI

Our AI-driven software tools support early detection, differential diagnosis, prediction of progression, and monitoring of neurodegenerative disorders.

cMRI

cMRI provides fully automated brain MRI quantification for increased throughput, greater objectivity, and high-quality reporting for improved patient care.

Play Video

Clinically focused cMRI reports

Our new clinically focused cMRI reports facilitate patient management as well as communication between radiologists, neurologists, patients, and their caregivers. These include reports for:

Dementia Differential Analysis report

The new Dementia Differential Analysis report is based on MRI data only, using our cDSI application’s proprietary machine learning method that measures the similarity of disease-specific imaging biomarker values from the patient to those from 2,000+ patients with a confirmed neurodegenerative disease: